Literature DB >> 31352525

Primary Aldosteronism: Cardiovascular Outcomes Pre- and Post-treatment.

Gregory L Hundemer1.   

Abstract

PURPOSE OF REVIEW: Primary aldosteronism (PA) is a common form of hypertension characterized by autonomous aldosterone secretion from one or both adrenal glands. The purpose of this review is to synthesize recent research findings regarding cardiovascular disease risk in PA both pre- and post-targeted therapy. RECENT
FINDINGS: Previously considered a rare disease, recent prevalence studies demonstrate that PA is actually a very common, yet vastly under-diagnosed, etiology of hypertension. Prior to targeted therapy, PA is associated with substantially higher rates of cardiovascular disease compared with essential hypertension. Surgical adrenalectomy is highly effective in curing or improving hypertension as well as mitigating cardiovascular disease risk in patients with unilateral PA. For the remainder of PA patients, MR antagonists are recommended; however, several recent studies have brought into question their effectiveness in improving cardiovascular outcomes. PA is a common cause of hypertension that leads to disproportionately high rates of cardiovascular disease. Future studies are needed to enhance the clinical approach to both identification and treatment of patients with PA to optimize long-term cardiovascular outcomes.

Entities:  

Keywords:  Atrial fibrillation; Cardiovascular disease; Conn’s syndrome; Mineralocorticoid receptor antagonist; Primary aldosteronism; Primary hyperaldosteronism

Mesh:

Substances:

Year:  2019        PMID: 31352525     DOI: 10.1007/s11886-019-1185-x

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  96 in total

1.  Hyperaldosteronism among black and white subjects with resistant hypertension.

Authors:  David A Calhoun; Mari K Nishizaka; Mohammad A Zaman; Roopal B Thakkar; Paula Weissmann
Journal:  Hypertension       Date:  2002-12       Impact factor: 10.190

2.  Laparoscopic management of primary hyperaldosteronism: clinical experience with 212 cases.

Authors:  Paul Meria; Béatrice Fiquet Kempf; Jean François Hermieu; Pierre François Plouin; Jean Marc Duclos
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

3.  Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading.

Authors:  Diego V Martinez; Ricardo Rocha; Mamiko Matsumura; Eveline Oestreicher; Margarita Ochoa-Maya; Weranuj Roubsanthisuk; Gordon H Williams; Gail K Adler
Journal:  Hypertension       Date:  2002-02       Impact factor: 10.190

4.  Laparoscopic adrenalectomy is superior to an open approach to treat primary hyperaldosteronism.

Authors:  J L Duncan; G M Fuhrman; J S Bolton; J D Bowen; W S Richardson
Journal:  Am Surg       Date:  2000-10       Impact factor: 0.688

5.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

6.  Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore.

Authors:  K C Loh; E S Koay; M C Khaw; S C Emmanuel; W F Young
Journal:  J Clin Endocrinol Metab       Date:  2000-08       Impact factor: 5.958

7.  Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.

Authors:  R Rocha; C T Stier; I Kifor; M R Ochoa-Maya; H G Rennke; G H Williams; G K Adler
Journal:  Endocrinology       Date:  2000-10       Impact factor: 4.736

8.  Primary hyperaldosteronism in the era of laparoscopic adrenalectomy.

Authors:  Heather Rossi; Anthony Kim; Richard A Prinz
Journal:  Am Surg       Date:  2002-03       Impact factor: 0.688

9.  Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism.

Authors:  Gian Paolo Rossi; Vitantonio Di Bello; Chiara Ganzaroli; Alfredo Sacchetto; Maurizio Cesari; Alessio Bertini; Davide Giorgi; Roldano Scognamiglio; Mario Mariani; Achille C Pessina
Journal:  Hypertension       Date:  2002-07       Impact factor: 10.190

10.  Primary aldosteronism and hypertensive disease.

Authors:  Lorena Mosso; Cristian Carvajal; Alexis González; Adolfo Barraza; Fernando Avila; Joaquín Montero; Alvaro Huete; Alessandra Gederlini; Carlos E Fardella
Journal:  Hypertension       Date:  2003-06-09       Impact factor: 10.190

View more
  6 in total

1.  Development and validation of a novel diagnostic nomogram model to predict primary aldosteronism in patients with hypertension.

Authors:  Meng-Hui Wang; Nan-Fang Li; Qin Luo; Guo-Liang Wang; Mulalibieke Heizhati; Ling Wang; Lei Wang; Wei-Wei Zhang
Journal:  Endocrine       Date:  2021-05-24       Impact factor: 3.633

2.  Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism.

Authors:  Shivraj Grewal; Andin Fosam; Liam Chalk; Arjun Deven; Mari Suzuki; Ricardo Rafael Correa; Jenny E Blau; Andrew Paul Demidowich; Constantine A Stratakis; Ranganath Muniyappa
Journal:  Endocrine       Date:  2021-01-18       Impact factor: 3.633

3.  Screening for Primary Aldosteronism is Underutilized in Patients with Obstructive Sleep Apnea.

Authors:  Patricia C Conroy; Sophia Hernandez; Claire E Graves; Kathryn Chomsky-Higgins Menut; Sarah Pearlstein; Chienying Liu; Wen T Shen; Jessica Gosnell; Julie A Sosa; Sanziana Roman; Quan-Yang Duh; Insoo Suh
Journal:  Am J Med       Date:  2021-09-09       Impact factor: 5.928

4.  Re-Assessment of the Oral Salt Loading Test Using a New Chemiluminescent Enzyme Immunoassay Based on a Two-Step Sandwich Method to Measure 24-Hour Urine Aldosterone Excretion.

Authors:  Yoshinori Ozeki; Mizuki Kinoshita; Shotaro Miyamoto; Yuichi Yoshida; Mitsuhiro Okamoto; Koro Gotoh; Takayuki Masaki; Kengo Kambara; Hirotaka Shibata
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-21       Impact factor: 5.555

5.  Functional imaging with 11C-metomidate PET for subtype diagnosis in primary aldosteronism.

Authors:  Minna Soinio; Anna-Kaarina Luukkonen; Marko Seppänen; Jukka Kemppainen; Janne Seppänen; Juha-Pekka Pienimäki; Helena Leijon; Tiina Vesterinen; Johanna Arola; Eila Lantto; Semi Helin; Ilkka Tikkanen; Saara Metso; Tuomas Mirtti; Ilkka Heiskanen; Leena Norvio; Mirja Tiikkainen; Tuula Tikkanen; Timo Sane; Matti Välimäki; Celso E Gomez-Sanchez; Ilkka Pörsti; Pirjo Nuutila; Pasi I Nevalainen; Niina Matikainen
Journal:  Eur J Endocrinol       Date:  2020-12       Impact factor: 6.664

6.  Screening for primary aldosteronism in the hypertensive obstructive sleep apnea population is cost-saving.

Authors:  Kathryn Chomsky-Higgins Menut; Sarah Sims Pearlstein; Patricia C Conroy; Sanziana A Roman; Wen T Shen; Jessica Gosnell; Julie Ann Sosa; Quan-Yang Duh; Insoo Suh
Journal:  Surgery       Date:  2021-07-06       Impact factor: 4.348

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.